MENLO PARK, Calif.–(BUSINESS WIRE)–MedaSystems, a leading provider of secure, validated software for Expanded Access Programs (EAPs) and Post-Trial Access (PTA), today announced new research demonstrating how its AI technology can unlock valuable insights from real-world patient data.The research demonstrates how MedaSystems is extending the value of its platform beyond managing the complex workflows and compliance requirements of Expanded Access Programs to helping pharmaceutical companies an
